Butterfly Medical Ltd.
Developer of an implantable, minimally invasive device intended to treat benign prostatic hyperplasia (BPH). The device is described as non-surgical, reversible, suitable for outpatient settings and local anesthesia, and has received CE marking for Europe. The device is investigational in the United States.
Industries
N/A
Nr. of Employees
small (1-50)
Butterfly Medical Ltd.
Beit Tavor 2nd entrance, 3rd floor, Yokneam 20692, Israel
Patents
Products
Implantable device for treatment of benign prostatic hyperplasia (BPH)
An implantable device intended to retract prostatic tissue to relieve urinary obstruction caused by BPH without cutting, burning, or puncturing tissue.
Implantable device for treatment of benign prostatic hyperplasia (BPH)
An implantable device intended to retract prostatic tissue to relieve urinary obstruction caused by BPH without cutting, burning, or puncturing tissue.
Services
Sponsoring and running clinical evaluations of an implantable BPH device under investigational status.
Conduct of early clinical evaluations to demonstrate safety and performance of the implantable device.
Sponsoring and running clinical evaluations of an implantable BPH device under investigational status.
Conduct of early clinical evaluations to demonstrate safety and performance of the implantable device.
Expertise Areas
- Implantable device development
- Minimally invasive urology interventions
- Clinical trial design and execution (urology)
- Regulatory strategy and CE marking
Key Technologies
- Implantable medical device engineering
- Minimally invasive procedure design
- Reversible implant mechanisms
- Outpatient procedural workflows
News & Updates
Participation in the American Urology Association annual conference to engage with urology clinicians and companies.
Company secured a competitive non-dilutive grant from the European Innovation Council and participation in future equity financing.
Announcement of a new CEO with prior experience launching a minimally invasive BPH treatment in the U.S.
Device has obtained CE mark for distribution/clinical use in Europe.
Awarded a non-dilutive grant from the European Innovation Council.
Participation in the American Urology Association annual conference to engage with urology clinicians and companies.
Company secured a competitive non-dilutive grant from the European Innovation Council and participation in future equity financing.
Announcement of a new CEO with prior experience launching a minimally invasive BPH treatment in the U.S.
Device has obtained CE mark for distribution/clinical use in Europe.
Awarded a non-dilutive grant from the European Innovation Council.